Patient population for bioequivalence study [Regulatives / Guidelines]

posted by pash413 – India, 2017-10-06 17:33 (1998 d 07:27 ago) – Posting: # 17867
Views: 3,068

Dear David
Thanks for the reply.
We are talking about the generic drug with PK endpoint study submission.

Complete thread:

UA Flag
 Admin contact
22,554 posts in 4,724 threads, 1,606 registered users;
17 visitors (1 registered, 16 guests [including 8 identified bots]).
Forum time: 01:00 CEST (Europe/Vienna)

Learning of many things
does not teach intelligence.    Heraclitus of Ephesus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz